TACR2 and breast carcinoma: Both peptides augmented the expression of NK-2R and NK-1R on the metastatic breast cancer cell line and, in addition, promoted the release from these cells of the high-molecular-weight kininogen molecule (bradykinin precursor) which exerted tumorigenic and pro-nociceptive actions [141].